TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
1.690
+0.040 (2.42%)
Jun 23, 2025, 4:00 PM - Market closed
TELA Bio Stock Forecast
Stock Price Forecast
The 4 analysts that cover TELA Bio stock have a consensus rating of "Strong Buy" and an average price target of $6, which forecasts a 255.03% increase in the stock price over the next year. The lowest target is $2 and the highest is $8.
Price Target: $6 (+255.03%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for TELA Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $7 | Strong Buy | Maintains | $12 → $7 | +314.20% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +314.20% | Mar 21, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $5 → $2 | Buy → Hold | Downgrades | $5 → $2 | +18.34% | Mar 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +195.86% | Nov 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +610.06% | Oct 4, 2024 |
Financial Forecast
Revenue This Year
87.78M
from 69.30M
Increased by 26.67%
Revenue Next Year
107.65M
from 87.78M
Increased by 22.63%
EPS This Year
-0.73
from -1.33
EPS Next Year
-0.42
from -0.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 90.9M | 115.6M | 141.8M | |
| Avg | 87.8M | 107.7M | 130.6M | |
| Low | 83.3M | 99.6M | 118.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 31.2% | 31.7% | 31.7% | |
| Avg | 26.7% | 22.6% | 21.4% | |
| Low | 20.2% | 13.4% | 10.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.65 | -0.20 | 0.22 | |
| Avg | -0.73 | -0.42 | 0.12 | |
| Low | -0.74 | -0.56 | 0.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.